CYP2C19基因型与冠心病精准抗血小板治疗

doi:10.16138/j.1673-6087.2021.03.005

摘要/Abstract

关键词: CYP2C19基因型, 冠心病, 急性冠脉综合征, 经皮冠状动脉介入治疗, 抗血小板治疗

中图分类号:

R541.4

刘晓丽, 马晓腾. CYP2C19基因型与冠心病精准抗血小板治疗[J]. 内科理论与实践, 2021, 16(03): 161-166.

参考文献 30

[1]	Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention[J]. JACC Cardiovasc Interv, 2019, 12(16): 1521-1537. doi: 10.1016/j.jcin.2019.03.034 URL
[2]	Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel[J]. N Engl J Med, 2009, 360(4): 354-362. doi: 10.1056/NEJMoa0809171 URL
[3]	Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361(11): 1045-1057. doi: 10.1056/NEJMoa0904327 URL
[4]	Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2007, 357(20): 2001-2015. doi: 10.1056/NEJMoa0706482 URL
[5]	Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology[J]. Eur Heart J, 2011, 32(15): 1854-1864. doi: 10.1093/eurheartj/ehr204 URL
[6]	Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial[J]. Lancet, 2010, 376(9749): 1320-1328. doi: 10.1016/S0140-6736(10)61274-3 pmid: 20801498
[7]	Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy[J]. Pharmgenomics Pers Med, 2011, 4: 123-136. doi: 10.2147/PGPM.S15497 pmid: 23226058
[8]	Levine GN, Jeong YH, Goto S, et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Nat Rev Cardiol, 2014, 11(10): 597-606. doi: 10.1038/nrcardio.2014.104 pmid: 25154978
[9]	Xi Z, Fang F, Wang J, et al. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations[J]. Platelets, 2019, 30(2): 229-240. doi: 10.1080/09537104.2017.1413178 URL
[10]	Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update[J]. Clin Pharmacol Ther, 2013, 94(3): 317-323. doi: 10.1038/clpt.2013.105 pmid: 23698643
[11]	Cao Y, Li L, Xu M, et al. The ChinaMAP analytics of deep whole genome sequences in 10,588 individuals[J]. Cell Res, 2020, 30(9): 717-731. doi: 10.1038/s41422-020-0322-9 URL
[12]	Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis[J]. JAMA, 2010, 304(16): 1821-1830. doi: 10.1001/jama.2010.1543 URL
[13]	Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis[J]. Circ Cardiovasc Genet, 2014, 7(6): 895-902. doi: 10.1161/CIRCGENETICS.114.000669 URL
[14]	Biswas M, Kali SK. Association of CYP2C19 loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: meta-analysis[J]. Cardiovasc Drugs Ther, 2021. [Epub ahead of print].
[15]	Zhang L, Yang J, Zhu X, et al. Effect of high-dose clopidogrel according to CYP2C192* genotype in patients undergoing percutaneous coronary intervention-a systematic review and meta-analysis[J]. Thromb Res, 2015, 135(3): 449-458. doi: 10.1016/j.thromres.2014.12.007 URL
[16]	Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C1917*allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation, 2010, 121(4): 512-518. doi: 10.1161/CIRCULATIONAHA.109.885194 pmid: 20083681
[17]	Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C1917*: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients[J]. J Thromb Haemost, 2012, 10(2): 199-206. doi: 10.1111/j.1538-7836.2011.04570.x pmid: 22123356
[18]	Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 17* polymorphism with increased activation of clopidogrel on cardiovascular events[J]. Am Heart J, 2010, 160(3): 506-512. doi: 10.1016/j.ahj.2010.06.039 pmid: 20826260
[19]	Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C1917* variant is not independently associated with clopidogrel response[J]. J Thromb Haemost, 2013, 11(9): 1640-1646. doi: 10.1111/jth.12342 pmid: 23809542
[20]	Lewis JP, Backman JD, Reny JL, et al. Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients[J]. Eur Heart J Cardiovasc Pharmacother, 2020, 6(4): 203-210. doi: 10.1093/ehjcvp/pvz045 URL
[21]	Lee CR, Thomas CD, Beitelshees AL, et al. Impact of the CYP2C1917* allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention[J]. Clin Pharmacol Ther, 2021, 109(3): 705-715. doi: 10.1002/cpt.2039 URL
[22]	Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons[J]. J Am Coll Cardiol, 2010, 56(4): 321-341. doi: 10.1016/j.jacc.2010.05.013 pmid: 20633831
[23]	Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention[J]. Circulation, 2011, 124(23): e574-e651.
[24]	Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease[J]. J Am Coll Cardiol, 2016, 68(10): 1082-1115. doi: 10.1016/j.jacc.2016.03.513 pmid: 27036918
[25]	Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg, 2018, 53(1): 34-78. doi: 10.1093/ejcts/ezx334 pmid: 29045581
[26]	Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477. doi: 10.1093/eurheartj/ehz425 URL
[27]	Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2021, 42(14): 1289-1367. doi: 10.1093/eurheartj/ehaa575 URL
[28]	Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2018, 71(17): 1869-1877. doi: S0735-1097(18)33306-0 pmid: 29540324
[29]	Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI[J]. N Engl J Med, 2019, 381(17): 1621-1631. doi: 10.1056/NEJMoa1907096 URL
[30]	Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention[J]. JAMA, 2020, 324(8): 761-771. doi: 10.1001/jama.2020.12443 pmid: 32840598

CYP2C19基因型与冠心病精准抗血小板治疗

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡健, 杨震坤, 闫小响, 杜润, 丁风华, 刘俊. 经皮冠状动脉介入术和冠状动脉旁路移植术对80岁以上左前支慢性闭塞患者的疗效比较[J]. 内科理论与实践, 2022, 17(01): 70-72.
[2]	杨洋, 龚艳春. 无症状高尿酸血症与心血管疾病和肾脏疾病关系的研究进展[J]. 内科理论与实践, 2021, 16(05): 366-370.
[3]	金姚, 黄晖, 吴志俊. 分泌性白细胞蛋白酶抑制剂与急性冠脉综合征的关系[J]. 内科理论与实践, 2021, 16(04): 251-254.
[4]	陆浩, 葛雷. 慢性完全闭塞病变介入治疗临床研究进展[J]. 内科理论与实践, 2021, 16(03): 145-150.
[5]	王墨扬, 陈阳, 叶蕴青, 张洪亮, 吴永健. 主动脉瓣狭窄合并冠心病患者的经导管主动脉瓣置换联合介入治疗[J]. 内科理论与实践, 2021, 16(03): 151-154.
[6]	钱杰. 血管内超声指导冠状动脉左主干介入治疗[J]. 内科理论与实践, 2021, 16(03): 155-160.
[7]	陈航炜, 戴秋艳. 冠心病的精准治疗[J]. 内科理论与实践, 2021, 16(03): 212-216.
[8]	吴洁, 冯媛媛, 任妍, 曹久妹. 基于冠状动脉造影检查的高龄老年人群发生冠心病的危险因素调查及相应诊断模型的建立[J]. 诊断学理论与实践, 2021, 20(02): 201-206.
[9]	陈燕, 李红鹏, 李诗琪, 张柳, 沈继敏, 李庆云,. 冠心病合并阻塞性睡眠呼吸暂停-慢性阻塞性肺疾病重叠综合征1例[J]. 内科理论与实践, 2019, 14(06): 379-380.
[10]	胡健, 张瑞岩, 杨震坤, 丁风华, 沈卫峰,. 血管内超声在无保护左主干病变介入治疗中的应用[J]. 内科理论与实践, 2017, 12(02): 120-122.
[11]	胡健, 张瑞岩, 杨震坤, 丁风华, 沈卫峰,. 介入治疗和冠状动脉旁路移植术对高龄无保护左主干病变患者的疗效比较[J]. 内科理论与实践, 2017, 12(01): 46-49.
[12]	王芳, 章安迪,. 伴有多种危险因素的冠心病患者支架内再狭窄的影响因素[J]. 诊断学理论与实践, 2016, 15(03): 280-282.
[13]	许庆玲, 杨肖波, 吴超, 唐陈月, 俞丽芬,. 上海冠心病患者结肠直肠腺瘤患病率的横断面调查[J]. 诊断学理论与实践, 2016, 15(01): 47-52.
[14]	阚通, 陈亮, 章伟, 那剑, 储国俊, 张燕, 赵仙先, 秦永文,. 血清同型半胱氨酸水平与糖尿病合并冠心病患者冠状动脉病变程度的相关性[J]. 内科理论与实践, 2015, 10(06): 421-423.
[15]	陈炽华, 严福华,. 心外膜脂肪组织与心血管疾病关系的研究近况[J]. 诊断学理论与实践, 2015, 14(05): 468-472.